More on KURA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.70 |
|
|||
| Open | $9.68 | ||||
| 52 Wk High | $8.90 | ||||
| 52 Wk Low | $2.50 | ||||
| Day High | $9.68 | ||||
| Day Low | $9.05 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,781,854 | ||||
- Kura Oncology (KURA) Reiterated at Overweight by Cantor Fitzgerald After Webinar on KO-7246
- Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on Preclinical Data for KO-7246
- Kura Oncology and Caspian outline diabetes drug development plan
- Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
- Caspian Therapeutics and Kura Oncology to host investor webcast
- Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
- UBS Reiterates Buy Rating on Kura Oncology (KURA)
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- JPMorgan Starts Kura Oncology (KURA) at Overweight
- Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: Bair Teresa Brophy
Entities mentioned with KURA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
